Literature DB >> 9464841

Enhanced expression of eotaxin and CCR3 mRNA and protein in atopic asthma. Association with airway hyperresponsiveness and predominant co-localization of eotaxin mRNA to bronchial epithelial and endothelial cells.

S Ying1, D S Robinson, Q Meng, J Rottman, R Kennedy, D J Ringler, C R Mackay, B L Daugherty, M S Springer, S R Durham, T J Williams, A B Kay.   

Abstract

Eotaxin is a newly discovered C-C chemokine which preferentially attracts and activates eosinophil leukocytes by acting specifically on its receptor CCR3. The airway inflammation characteristic of asthma is believed to be, at least in part, the result of eosinophil-dependent tissue injury. This study was designed to determine whether there is increased expression of eotaxin and CCR3 in the bronchial mucosa of asthmatics and whether this is associated with disease severity. The major sources of eotaxin and CCR3 mRNA were determined by co-localization experiments. Bronchial mucosal biopsy samples were obtained from atopic asthmatics and normal non-atopic controls. Eotaxin and CCR3 mRNA were identified in tissue sections by in situ hybridization (ISH) using radiolabeled riboprobes and their protein product visualized by immunohistochemistry (IHC). Co-localization experiments were performed by double ISH/IHC. Eotaxin and CCR3 (mRNA and protein) were significantly elevated in atopic asthmatics compared with normal controls. In the asthmatics there was a highly significant inverse correlation between eotaxin mRNA+ cells and the histamine provocative concentration causing a 20% fall in FEV1 (PC20). Cytokeratin-positive epithelial cells and CD31+ endothelial cells were the major source of eotaxin mRNA whereas CCR3 co-localized predominantly to eosinophils. These data are consistent with the hypothesis that damage to the bronchial mucosa in asthma involves secretion of eotaxin by epithelial and endothelial cells resulting in eosinophil infiltration mediated via CCR3. Since selective (eotaxin) and non-selective C-C chemokines such as RANTES, MCP-3 and MCP-4 all stimulate eosinophils via CCR3, this receptor is potentially a prime therapeutic target in the spectrum of diseases involving eosinophil-mediated tissue damage.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9464841     DOI: 10.1002/eji.1830271252

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  81 in total

Review 1.  Cytokines in asthma.

Authors:  K F Chung; P J Barnes
Journal:  Thorax       Date:  1999-09       Impact factor: 9.139

Review 2.  Eotaxin and asthma: some answers, more questions.

Authors:  C J Corrigan
Journal:  Clin Exp Immunol       Date:  1999-04       Impact factor: 4.330

Review 3.  Pathophysiological mechanisms of asthma. Application of cell and molecular biology techniques.

Authors:  K F Chung; I M Adcock
Journal:  Mol Biotechnol       Date:  2001-07       Impact factor: 2.695

Review 4.  Chemokines in allergic lung inflammation.

Authors:  Clare Lloyd
Journal:  Immunology       Date:  2002-02       Impact factor: 7.397

5.  Chemokines in the limbal form of vernal keratoconjunctivitis.

Authors:  A M Abu El-Asrar; S Struyf; S A Al-Kharashi; L Missotten; J Van Damme; K Geboes
Journal:  Br J Ophthalmol       Date:  2000-12       Impact factor: 4.638

Review 6.  Cytokine expression in allergic inflammation: systematic review of in vivo challenge studies.

Authors:  Manuel A R Ferreira
Journal:  Mediators Inflamm       Date:  2003-10       Impact factor: 4.711

7.  Inhibitory effect of CCR3 signal on alkali-induced corneal neovascularization.

Authors:  Wen-Juan Zhou; Gao-Qin Liu; Long-Biao Li; Xue-Guang Zhang; Pei-Rong Lu
Journal:  Int J Ophthalmol       Date:  2012-06-18       Impact factor: 1.779

8.  Eotaxin expression in Sephadex-induced lung injury in rats.

Authors:  R F Guo; P A Ward; J A Jordan; M Huber-Lang; R L Warner; M M Shi
Journal:  Am J Pathol       Date:  1999-12       Impact factor: 4.307

9.  Neuronal eotaxin and the effects of CCR3 antagonist on airway hyperreactivity and M2 receptor dysfunction.

Authors:  Allison D Fryer; Louis H Stein; Zhenying Nie; Damian E Curtis; Christopher M Evans; Simon T Hodgson; Peter J Jose; Kristen E Belmonte; Erin Fitch; David B Jacoby
Journal:  J Clin Invest       Date:  2005-12-22       Impact factor: 14.808

10.  Local proliferation and mobilization of CCR3(+)  CD34(+) eosinophil-lineage-committed cells in the lung.

Authors:  Madeleine Rådinger; Apostolos Bossios; Margareta Sjöstrand; You Lu; Carina Malmhäll; Anna-Karin Dahlborn; James J Lee; Jan Lötvall
Journal:  Immunology       Date:  2010-09-28       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.